Biofrontera Inc. (BFRI)

1.2800 -0.0100 (-0.78%) At close: 04:00PM EDT

Biofrontera Inc.

120 Presidential Way
Suite 330
Woburn, MA 01801
United States
781-245-1325
https://www.biofrontera-us.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 83

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hermann Luebbert Ph.D.	CEO, President & Executive Chairman	733.23k	N/A	1956
Mr. Eugene Frederick Leffler III	Chief Financial Officer	378.58k	N/A	1985
Ms. Erica F. Gates CPA, M.B.A.	Senior Director of Finance & Principal Accounting Officer	N/A	N/A	N/A
Mr. Jon Lyons M.B.A., Ph.D.	Vice President of Scientific & Medical Affairs	N/A	N/A	N/A
Ms. Alycia Torres	Vice President of Administration	N/A	N/A	N/A
Mr. Daniel Hakansson J.D.	General Counsel & Head of Compliance	N/A	N/A	N/A
Mr. Mark Baldyga	Vice President of Sales & Marketing	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.